Bristol-Myers Squibb, NYSE and Inspire Trust Co

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...
Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.